发布求助
文献互助 智能选刊 最新文献

Drug and Therapeutics Bulletin最新文献

筛选
英文 中文
Prenatal use of antiepileptic drugs and childhood psychiatric disorders 产前使用抗癫痫药物与儿童精神障碍
Drug and Therapeutics Bulletin Pub Date : 2024-04-27 DOI: 10.1136/dtb.2024.000026
BMJ Publishing Group Ltd
{"title":"Prenatal use of antiepileptic drugs and childhood psychiatric disorders","authors":"BMJ Publishing Group Ltd","doi":"10.1136/dtb.2024.000026","DOIUrl":"https://doi.org/10.1136/dtb.2024.000026","url":null,"abstract":"### Key learning points A registry-based study has reinforced the need for safety warnings against using valproate during pregnancy because of an increased risk of early-onset developmental disorders in exposed children.1 This prospective cohort study used data on live-born singleton children of mothers with epilepsy from five Nordic countries to examine the association between prenatal use of antiepileptic medication and psychiatric and developmental disorders in exposed offspring.1 Children were followed up from birth until the …","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":"38 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140809356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cytisine for smoking cessation. 用于戒烟的 Cytisine。
Drug and Therapeutics Bulletin Pub Date : 2024-04-25 DOI: 10.1136/dtb.2024.000009
{"title":"Cytisine for smoking cessation.","authors":"","doi":"10.1136/dtb.2024.000009","DOIUrl":"https://doi.org/10.1136/dtb.2024.000009","url":null,"abstract":"","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":"10 7","pages":"71-76"},"PeriodicalIF":0.0,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140658387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 16
Recent updates from the BNF (BNF 87). BNF 的最新更新（BNF 87）。
Drug and Therapeutics Bulletin Pub Date : 2024-04-25 DOI: 10.1136/dtb.2024.000018
{"title":"Recent updates from the <i>BNF</i> (<i>BNF</i> 87).","authors":"","doi":"10.1136/dtb.2024.000018","DOIUrl":"10.1136/dtb.2024.000018","url":null,"abstract":"<p><p>The BNF is jointly published by the Royal Pharmaceutical Society and BMJ. BNF is published in print twice a year and interim updates are issued and published monthly in the digital versions. The following summary provides a brief description of some recent key changes that have been made to BNF content.</p>","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"68-70"},"PeriodicalIF":0.0,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140189589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Delayed drug hypersensitivity reaction to secukinumab in a patient with hidradenitis suppurativa. 一名化脓性扁桃体炎患者对塞库单抗的迟发性药物超敏反应。
Drug and Therapeutics Bulletin Pub Date : 2024-04-25 DOI: 10.1136/dtb.2023.249684rep
Sasank Konda, Nayha Shetty, Ben Friedman, Jesse Veenstra
{"title":"Delayed drug hypersensitivity reaction to secukinumab in a patient with hidradenitis suppurativa.","authors":"Sasank Konda, Nayha Shetty, Ben Friedman, Jesse Veenstra","doi":"10.1136/dtb.2023.249684rep","DOIUrl":"10.1136/dtb.2023.249684rep","url":null,"abstract":"","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"77-79"},"PeriodicalIF":0.0,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9752554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medicines and global warming: a complex problem 药品与全球变暖：一个复杂的问题
Drug and Therapeutics Bulletin Pub Date : 2024-04-09 DOI: 10.1136/dtb.2024.000003
James A Cave
{"title":"Medicines and global warming: a complex problem","authors":"James A Cave","doi":"10.1136/dtb.2024.000003","DOIUrl":"https://doi.org/10.1136/dtb.2024.000003","url":null,"abstract":"The healthcare sector is responsible for 4.6% of global greenhouse gas emissions.1 Significant contributors to this carbon footprint are the biotech and pharmaceutical industries, directly from the running of these companies (sometimes called scope 1 emissions) and indirectly from purchased energy consumed (scope 2 emissions) and all other emissions indirectly associated with the companies—such as supply chains (scope 3 emissions).2 It is estimated that scope 1, 2 and 3 emissions of biotech and pharmaceutical companies accounted for 260 million tons of carbon dioxide equivalent emissions in 2021, higher than global emissions from the forestry and paper industry.2 There are particular …","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":"61 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140593984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MHRA issues further update on fluoroquinolone safety MHRA 发布氟喹诺酮类药物安全性的进一步更新信息
Drug and Therapeutics Bulletin Pub Date : 2024-04-09 DOI: 10.1136/dtb.2024.000021
BMJ Publishing Group Ltd
{"title":"MHRA issues further update on fluoroquinolone safety","authors":"BMJ Publishing Group Ltd","doi":"10.1136/dtb.2024.000021","DOIUrl":"https://doi.org/10.1136/dtb.2024.000021","url":null,"abstract":"### Key learning points The licensed indications for all systemic fluoroquinolones have been updated to restrict their use to situations in which other commonly recommended antibiotics are inappropriate.1 In August and September 2023, the Medicines and Healthcare products Regulatory Agency (MHRA) issued two safety updates on the use of fluoroquinolone antibiotics.1–3 The first update reminded healthcare professionals that systemic fluoroquinolone antibiotics are associated with a risk of …","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":"65 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140594014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Donanemab in early symptomatic Alzheimer’s disease 多奈单抗治疗早期症状阿尔茨海默病
Drug and Therapeutics Bulletin Pub Date : 2024-04-05 DOI: 10.1136/dtb.2024.000020
BMJ Publishing Group Ltd
{"title":"Donanemab in early symptomatic Alzheimer’s disease","authors":"BMJ Publishing Group Ltd","doi":"10.1136/dtb.2024.000020","DOIUrl":"https://doi.org/10.1136/dtb.2024.000020","url":null,"abstract":"### Key learning points The authors of a phase 3 trial involving people with early Alzheimer’s disease (AD) reported that although donanemab produced a small reduction in clinical progression compared with placebo, it was associated with some serious adverse effects.1 The TRAILBLAZER-ALZ 2 trial was a 76-week, phase 3, randomised, double-blind, placebo-controlled study that recruited participants aged 60–85 years with early symptomatic AD, a Mini-Mental State Examination score of 20–28 and confirmed amyloid and tau pathology assessed by positron emission tomography (PET) scans.1 A total of 1736 …","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":"65 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140593996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Do regulatory safety warnings on medicines miss the mark? 药品的监管安全警告是否失误？
Drug and Therapeutics Bulletin Pub Date : 2024-03-25 DOI: 10.1136/dtb.2023.000053
Barbara Mintzes
{"title":"Do regulatory safety warnings on medicines miss the mark?","authors":"Barbara Mintzes","doi":"10.1136/dtb.2023.000053","DOIUrl":"10.1136/dtb.2023.000053","url":null,"abstract":"","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"50"},"PeriodicalIF":0.0,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140065052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety update: valproate safety and educational materials. 安全性更新：丙戊酸钠的安全性和教育材料。
Drug and Therapeutics Bulletin Pub Date : 2024-03-25 DOI: 10.1136/dtb.2024.000013
{"title":"Safety update: valproate safety and educational materials.","authors":"","doi":"10.1136/dtb.2024.000013","DOIUrl":"10.1136/dtb.2024.000013","url":null,"abstract":"<p><p><b>Overview of:</b> Medicines and Healthcare products Regulatory Agency. Valproate (Belvo, Convulex, Depakote, Dyzantil, Epilim, Epilim Chrono or Chronosphere, Episenta, Epival and Syonell▼): new safety and educational materials to support regulatory measures in men and women under 55 years of age. Drug Safety Update 2024;17:1.</p>","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"53"},"PeriodicalIF":0.0,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139989528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Does oseltamivir prevent hospitalisation in people with influenza? 奥司他韦能否预防流感患者住院？
Drug and Therapeutics Bulletin Pub Date : 2024-03-25 DOI: 10.1136/dtb.2024.000016
{"title":"Does oseltamivir prevent hospitalisation in people with influenza?","authors":"","doi":"10.1136/dtb.2024.000016","DOIUrl":"10.1136/dtb.2024.000016","url":null,"abstract":"<p><p><b>Overview of:</b> Hanula R, Bortolussi-Courval É, Mendel A, et al. Evaluation of oseltamivir used to prevent hospitalization in outpatients with influenza: a systematic review and meta-analysis. JAMA Internal Medicine 2024;184:18-27.</p>","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":"62 4","pages":"52"},"PeriodicalIF":0.0,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140287105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信